Sepracor boosts DSP's top line but generics bite at home
This article was originally published in Scrip
Executive Summary
The consolidation of fourth-quarter figures for its US acquisition Sepracor boosted Dainippon Sumitomo Pharma's (DSP) top line by ¥28.6 billion ($306 million) in the fiscal year to 31 March.